Funded Biotechnology Startups in Austin
Among the 26 Austin-area biotech rounds shown, the largest disclosed amount is Shattuck Labs at $75M (2026-06-10).
Among the 26 Austin-area biotech rounds shown, the largest disclosed amount is Shattuck Labs at $75M (2026-06-10). That top round sits above the next-largest disclosed amounts of $55M (Triumvira Immunologics, 2020-08-27) and $50M (Rein Therapeutics, 2026-04-30), but it does not dwarf them the way smaller “tail” values do: several other meaningful rounds cluster in the $38M–$47M band (e.g., Parachute $38M on 2026-04-16; Trace $47M on 2022-04-12; Cassava Sciences $47M on 2022-11-18). Date-wise, rounds span 2020-08-27 through 2026-06-10, with multiple entries concentrated in mid-2025 and early 2026 (e.g., Parachute 2026-04-16; Rein Therapeutics 2026-04-30; Shattuck Labs 2026-06-10). Stage labeling is also uneven: five of the 26 rows are “Series Unknown,” and two are “undisclosed” amounts (Parhelia Biosciences on 2023-10-17; TFF Pharmaceuticals on 2023-05-01), which complicates any strict ranking beyond disclosed figures.
Most recent rounds
26 shownRelated listings
Frequently asked
What is the largest disclosed round here, and how much larger is it than the rest of the disclosed amounts?
Shattuck Labs’ $75M round (2026-06-10) is the largest disclosed amount across the 26 rows. It’s above Rein Therapeutics’ $50M (2026-04-30) and below the disclosed $55M Triumvira Immunologics figure (2020-08-27), so it leads a relatively tight high-end cluster rather than a long gap to the next disclosed rounds.
Do the most recent rounds cluster into a narrow time window rather than being evenly spread?
Yes. Multiple rounds land in spring to early summer 2026, including Parachute $38M (2026-04-16), Rein Therapeutics $50M (2026-04-30), and Shattuck Labs $75M (2026-06-10). That’s alongside another high-density period in 2025, such as Pattern Bioscience $44M (2025-08-18) and Maxwell Biosciences $20M (2025-08-05).
How dominant is “Series Unknown,” and does it limit comparisons by stage?
“Series Unknown” appears in five of the 26 rows (e.g., Shattuck Labs 2026-06-10 $75M; Rein Therapeutics 2026-04-30 $50M; Genprex 2025-10-28 $3M). In addition, two rounds have undisclosed amounts (Parhelia Biosciences 2023-10-17; TFF Pharmaceuticals 2023-05-01), further restricting stage-versus-size comparisons to the disclosed subset.
Are there stage clusters where larger disclosed amounts repeat (e.g., Series A or Series C)?
Series A includes QbDVision $13M (2025-05-01) and Phantom Neuro $19M (2025-04-15), which are mid-sized relative to the overall disclosed range. Series C shows two $38M–$47M entries (L7 Informatics $38M on 2022-06-07 and Trace $47M on 2022-04-12), indicating that some later-stage labels align with the upper tier of disclosed round sizes in this list.
Which entries are the notable outliers on disclosed size, and what are the nearest disclosed neighbors?
The smallest disclosed amount is EQO’s $100K (2022-10-01, Pre-Seed), which sits far below nearby low-ticket disclosed rounds like Paradromics $240K (2025-12-08). On the high end, Shattuck Labs’ $75M (2026-06-10) is the top disclosed figure, with the next-largest disclosed amounts at $55M (Triumvira Immunologics, 2020-08-27) and $50M (Rein Therapeutics, 2026-04-30).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.